Annovis Bio, Inc. (ANVS) · Oct 19, 2026 · Other events
Audit fees corrected — 2025 total fees $515,000 vs $482,045 in 2024
Annovis corrected a proxy-statement typo in its audit-fee disclosure. The filing changes reported fees, not the company’s clinical or funding story.
Annovis is a Phase 3 biotech advancing buntanetap for Alzheimer’s and Parkinson’s disease, with the business story centered on late-stage clinical development rather than operating revenue. This filing is administrative, not strategic. The company corrected a typographical error in its June 17, 2026 proxy statement; it does not change the drug program, financing position, trial timeline, or governance. 〔0〕
| Fee category | 2025 | 2024 |
|---|---|---|
| Audit fees | $415,000 | $375,000 |
| Audit-related fees | $100,000 | $107,045 |
| Total fees | $515,000 | $482,045 |
The corrected numbers show a modest year-over-year increase in total auditor fees, driven by higher audit fees but partly offset by lower audit-related fees (Corrected audit-fee table). There is no meaningful market benchmark or new expectation to beat here; this is a confirmation of corrected historical disclosure, not a new operating signal.
Bottom line: This filing cleans up the proxy record and leaves Annovis’s core clinical-development story unchanged. It is routine housekeeping, not a business catalyst or setback.icar
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!